Drugs / MK0812
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00239655 | Aug 2004 → Dec 2005 | relapsing-remitting multiple sclerosis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00542022 | Jun 2004 → May 2005 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK0812 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00542022 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 2 antagonist” CHEMBL3305901 ↗ |
| Modality | Small molecule | — CHEMBL3305901 ↗ |
| Target | CCR2 | “C-C chemokine receptor type 2 antagonist” CHEMBL3305901 ↗ |